Granata Bio Secures $15 Million to Advance Fertility Treatments
Granata Bio, a biopharma company focused on women’s health and infertility, has recently secured $15 million in Series A+ funding. This significant investment was exclusively supported by existing investors, including Gedeon Richter, CooperSurgical, Amboy Street Ventures, and other strategic investors. The funding brings the company’s total investment to over $30 million.
Founded in 2018, Granata Bio identifies strategic medications used in IVF outside of the US for clinical development and commercialization in North America. The company aims to improve access to fertility treatments by introducing new therapeutic solutions and reducing costs for patients. The US fertility medication market is undersaturated, and Granata Bio is committed to addressing this gap by optimizing therapeutics from ovarian stimulation to luteal phase support.
The latest funding round will primarily support Granata Bio’s efforts to advance its existing pipeline and explore new innovative assets in reproductive health. The company’s pipeline includes collaborations across multiple IVF product classes, demonstrating its comprehensive approach to addressing fertility challenges.
Granata Bio’s mission is to create access for fertility patients by introducing new therapeutic solutions. The company understands that the cost of IVF medications has increased by 50% since 2014, and fertility insurance coverage in the US is still patchy, leading to significant barriers to treatment. By developing new medications and therapeutic solutions, Granata Bio aims to reduce these costs and increase access to care for every patient seeking fertility treatment.
The company’s team has over 75 years of experience in reproductive health, with expertise in clinical development, regulatory requirements, and commercialization. Granata Bio is also a proud supporter of RESOLVE: The National Infertility Association and other patient advocacy groups, highlighting its commitment to the broader fertility community.
The recent funding demonstrates continued support from major players in women’s health. Gedeon Richter brings expertise in steroid chemistry and women’s healthcare, while CooperSurgical contributes experience in assisted reproductive technology and genomic solutions. This strategic partnership underscores the confidence and commitment shown by these investors in Granata Bio’s mission and vision.
With this new funding, Granata Bio is well-positioned to accelerate the development of its current and future pipeline. The company’s focus on improving access to fertility treatments and reducing costs for patients aligns with the growing need for innovative solutions in the US reproductive health market. By advancing its pipeline and exploring new assets, Granata Bio is poised to make a significant impact in the lives of individuals and families seeking fertility treatments.
See more funded startups in USA.